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Abstract A single amino acid substitution (Ala33SAsp) in cAMP 
binding site B of the regulatory subunit of cAMP-dependent 
protein kinase type I was sufficient o abolish high affinity cAMP 
binding for both cAMP binding sites A and B. Furthermore, the 
Ala33SAsp mutation increased the activation constant for cAMP 
of the mutant holoenzyme 30-fold and also enhanced the rate of 
holoenzyme formation. Thus, the substitution was responsible for 
the dominant negative phenotype of the enzyme. Activation of 
mutant holoenzyme with site-selective cAMP analogs indicated 
that the enzyme dissociated through binding to site A only. Our 
results provide evidence that Ala 335 is an essential residue for high 
affinity cAMP binding of both sites as well as for the functional 
integrity of the enzyme. 
B has been shown to interact with the adenine moiety since 
alteration of this residue changed the affinity and specificity for 
cGMP [13]. Recently, a sub-clone of the rat myelocytic leuke- 
mia cell line (IPC-81) has been found to harbor a heterozy- 
gously expressed point mutation [14]. This mutated clone was 
selected by treatment with 8-CPT-cAMP and identified as Ala- 
to-Asp at the invariant position 335 [14]. In order to study the 
effects of this mutation on ligand binding and holoenzyme 
activation we used recombinant protein expression techniques 
to obtain large quantities of pure recombinant Ala335Asp mu- 
tant protein. 
2. Materials and methods 
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1. Introduction 
The holoenzyme complex of the cAMP-dependent protein 
kinase (R2C2) consists of a regulatory subunit dimer (R2) and 
two catalytic subunits (C). Binding of cAMP to the regulatory 
subunits causes the complex to dissociate and subsequently 
release the active catalytic subunit (for reviews ee [1,2]). Each 
regulatory subunit monomer consists of two in-tandem cAMP 
binding sites at the C-terminal end of the protein [3]. In addi- 
tion, the N-terminus hosts the dimerisation region and the 
'hinge' region responsible for complexing the catalytic subunit 
[3,4]. The two cAMP binding sites are known to bind cAMP 
and cAMP analogs with different affinities [5,6]. Sequence 
alignment of the cAMP binding domains revealed the homol- 
ogy to the catabolite gene activator protein (CAP), and on the 
basis of the 2.5 A crystal structure of CAP a three-dimensional 
model for each cAMP binding site has been constructed [7,8]. 
The validity of this model as a general framework for the 
folding of the polypeptide chain in both cAMP binding sites is 
confirmed by photoaffinity labeling [9] and by analyzing mu- 
tant forms of the R I subunit defective in their cAMP binding 
sites [10-12]. The general features of the cAMP binding sites 
(A and B) include an invariant Arg (209 and 333) which binds 
to the phosphate moiety of cAMP, and an invariant Glu (200 
and 324) that hydrogen bonds to the T-OH of the ribose. 
Additional invariant residues are known but only Ala TM in site 
2.1. Mutagenesis 
The mutagenesis was performed by PCR 'overlap extension' [15]. 
Primary PCR reaction mixtures (100/~1) contained: 50 mM Tris, pH 9.0, 
50 mM KCI, 7 mM MgC12, 0.125 mM dNTPs, 0.2 mg/ml BSA, 16 mM 
(NH4)2SO4, 20 mM of primer A (5'-CGGCCCCGTGCAGATACCG- 
TGGTG-3') and B (5'-CTCGCATGCTCAGACAGACAGGGACA- 
CGA-3') or C (5'-ACCACGGTATCTGCAC-3') and D (5'-GATTA- 
CGAATTCCCCGGATCCGT-3'), 1 ng DNA (full-length pUC-7/R l 
cDNA clone) [16] and 0.1 U Super Taq-polymerase (HT Biotech). The 
amplified DNA products were purified and incubated with Klenow 
fragment before xtraction with Quiaex beads (Quiagen). A subsequent 
PCR reaction contained a mixture of the two primary PCR products 
and primers B and D. The final PCR product was purified, cut with 
EeoRI and SphI, ligated into pUC-7 and transformed into electro- 
competent E. coli JM109 cells. Positive clones (pUC-7/A335D-W) were 
selected and the amplified insert DNA sequenced according to the 
method escribed by Sanger [17]. 
2.2. Expression and purification of recombinant mutant and wild-type 
R 1 subunits 
4 1 of LB broth (100/~g/ml ampicillin) were inoculated with E. coli 
JM109 (pUC-7/A335D-R~). Cells were grown at 37°C for 24 h and the 
bacterial pellet subsequently resuspended in buffer A (10 mM potas- 
sium phosphate, pH 7.0, 15 mM fl-mercaptoethanol, 2 mM EDTA, 
2 mM benzamidine, 0.1 M NaCI, 100 mg/ml PMSF, 50 mg/ml SBTI, 
100 mg/ml TPCK and 50 mg/ml TLCK) and passed twice through a 
French pressure cell at 4°C. The homogenate was centrifuged and the 
protein purified to homogeneity on DEAE- and cAMP-agarose (8- 
AEA-cAMP) affinity chromatography. Holoenzyme was formed as 
described earlier [18] by dialysis of the R l subunit with a 10% molar 
excess ofC subunit. After dialysis excess ofC subunit was removed with 
CM-Sepharose. Catalytic activity was assayed by a coupled spectro- 
photometric method [19]. The synthetic peptide L-R-R-N-S-I was used 
as substrate [18]. The rate of holoenzyme formation was determined by
removing aliquots at indicated time points and comparing the remain- 
ing activity to wild-type nzyme. The expression and purification of 
wild-type Rj subunit was as described in [16]. 
*Corresponding author. Fax: (49) (3849) 3261. 
2.3. cAMP binding assays 
K D for wild-type and mutant R1 subunits and their holoenzymes were 
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determined by modification of a method escribed earlier [20]. Proteins 
were incubated in buffer A (50 mM MES, pH 6.9, 0.4 mM EGTA, 
1 mM Mg-acetate, 10 mM NaC1, 10 mM DTT and 0.5 mg/ml BSA) 
with varying concentrations of [3H]cAMP (Amersham). After 30 min 
incubation at 30°C aliquots were precipitated in 3 ml of ice-cold 95% 
ammoniumsulfate (with 10 mM HEPES-NaOH, pH 7.0, 2 mM EDTA) 
and filtered over 0.45 pm pore size nitrocellulose filters. To distinguish 
the two kinetically different cAMP binding sites [3H]cAMP bound to 
site A was selectively displaced by an excess of unlabeled cAMP during 
a 5 6 h incubation at 0°C as previously described [20]. 
cAMP dissociation rates (koff) were measured in the absence of C- 
subunit. The individual Rl-subunit proteins (50 nM) were saturated 
with [3H]cAMP (1 pM) during 30 min incubation at 30°C followed by 
30 rain at 0°C in a final volume of 100 pl binding buffer (with 60 mM 
HEPES-NaOH, pH 7.0, 60 mM EDTA, 20 mM DTT, 0.5 mg/ml BSA). 
Aliquots were added to dissociation buffer (15 mM HEPES-NaOH, pH 
7.0, 5 mM EDTA, 0.3 mM EGTA, 20 mM DTT, 0.5 mg/ml BSA, 4 M 
NaC1 and 1 mM cAMP). At designated time points, aliquots were 
removed, and [3H]cAMP that remained bound to R l subunit was meas- 
ured by the ammonium sulfate filtration assay as described above. 
2.4. Apparent activation constants (K,, ,pp) for cAMP and cAMP 
analogs 
Mutant and wild-type holoenzymes (10 nM) were incubated with the 
synthetic peptide L-R-R-N-S-I (40 pM), 0.1 mM [y-32p]ATP (Amer- 
sham; specific activity 150 cpm/pmol) and various concentrations of
cAMP or adenine-modified cAMP analogs. The phosphotransferase 
reaction was carried out for 2 rain at 30°C according to a method 
described previously [21]. Reactions were started by addition of the 
holoenzymes and terminated after 2 rain by spotting aliquots on 
phospho-cellulose trips and subsequently washed in 75 mM phos- 
phoric acid. 
3. Results 
3.1. Purification and cAMP-binding 
Expression and subsequent purification of the mutant 
Ala335Asp R ] subunit yielded a soluble and stable protein of 45 
kDa as judged from SDS-PAGE (data not shown). No prote- 
olytic degradation, which is prone to occur at the hinge region, 
was observed for the duration of the experiments. Since the 
mutant R I subunit was obtained from cAMP-agarose at the last 
purification step it obviously retained some cAMP binding 
capability. To further investigate the cAMP binding properties 
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Fig. 1. Rate of exchange of [3H]cAMP bound wild-type (©) and 
Ala335Asp regulatory subunit (e). The inset shows the initial rate en- 
larged. 
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Fig. 2. Rate of holoenzyme formation in the presence of MgATP for 
wild type (©) and mutant proteins (0). 
we determined the binding and dissociation constants and com- 
pared them to wild-type R I subunit. As shown in Fig. 1 and 
Table 1 the two cAMP binding sites in the wild-type R I subunit 
are readily distinguished by their cAMP dissociation rates. The 
rapid dissociation (kon- = 1.0 min -1) represents the exchange of 
cAMP bound to site A while the slower dissociation 
(kofr = 0.0167 min -]) is the exchange from site B [22]. Dissocia- 
tion rates were measured with high salt in the buffer, a condi- 
tion known to emphasize biphasic exchange [23]. In contrast, 
the cAMP dissociation rate of the mutant R I subunit was 
monophasic and rapid (kofr = 1.2 min -t, see inset of Fig. 1), 
indicating one functional class of 'binding site' per monomer. 
Equilibrium cAMP binding studies revealed that the wild- 
type protein bound 2 mol cAMP/mol subunit with KD values 
of 10 nM and 30 nM for binding site A and B, respectively. In 
contrast, the Ala335Asp mutant bound 1 mol cAMP/mol sub- 
unit with an apparent K D of 490 nM (Table 1). Thus, high 
affinity binding to the mutated site was not only abolished, but 
the mutation transmitted a change in binding interaction to the 
non-mutated binding site A as well. The corresponding mutant 
protein extracted from IPC-81 cells [14] showed a slightly 
higher affinity for site A compared to the data obtained in this 
Table 1 
Kinetic constants of wild-type and Ala33S/Asp mutant proteins 
Wild-type Ala 335/ 
Asp 
R ~ subunit 
Rate constant, koff (min -~) site A: 1.0 site B: 0.0167 1.2 
Dissociation constant, 22 490 
Ko (nM) 
Binding stochiometry 2 1 
Holoenzyme 
Activation constant, 170 5,000 
Ka,ap  p (nM)  
Dissociation constant, 165 2,800 
Ko (nM) 
Binding stochiometry 2 1 
The kinetic constants were determined as described in section 2. 
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Fig. 3. (a) The ability of 8-Methylamino-cAMP (1,circles) and 6-ben- 
zoyl-cAMP (9, triangles) to activate the wild-type (open symbols) and 
mutant holoenzyme (filled symbols). The shift for each analog is indi- 
cated by arrows. (b) The relative ability of cAMP analogs (o) to activate 
the Ala33SAsp mutant and wild-type holoenzymes (K~. app cAKI/Ka, avp 
cAK-R~aA335D) as a function of the A/B binding site selectivity for 
these cAMP analogs. The numbers in the double reciprocal plot indi- 
cate the individual cAMP analogs (see Table 2). 
study. This apparent discrepancy can be explained by (i) the 
different species as sources of the proteins, (ii) the higher con- 
centration of recombinant enzyme, or (iii) a possible macro- 
molecular aggregation fthe recombinant protein. When meas- 
uring equilibrium cAMP binding with mutant holoenzyme (see 
section 3.2) the binding constant (KD = 2.8 ~M) was increased 
even further (Table 1). 
3.2. Holoenzyme formation and activation 
In order to determine whether mutant R ~ subunit retained 
the ability to interact with the C subunit, Ala335Asp R I subunit 
was dialyzed in the presence of a 10% excess ofC subunit under 
conditions that would typically lead to the formation of holoen- 
zyme [18]. Holoenzyme formation was measured in the pres- 
ence of MgATP which previously had been shown to strongly 
increase the rate at which wild-type R I subunit associates with 
C subunit [24]. Under these conditions, the mutant R ~ subunit 
formed holoenzyme much faster than the wild-type protein 
(Fig. 2). In fact holoenzyme formation occured nearly spon- 
tanously and did not appear to require dialysis for displacement 
of cAMP (data not shown). 
The activation ofholoenzyme asa function of cAMP concen- 
tration was tested using the phosphotransferas as ay. The ap- 
parent activation constant (Ka, app) was measured in the pres- 
ence of MgATP, which is known to lower the affinity for cAMP 
and thereby the activation potential of the holoenzyme [10]. 
The cAMP concentration needed for half-maximal ctivation 
(Ka, app) of the mutant holoenzyme was 5 gM in comparison to 
170 nM for the wild-type protein (Table 2). Thus, by changing 
Ala 335 to Asp the Ka. app value increased 30-fold. 
3.3. cAMP-analog specificity 
Since the two cAMP binding sites in the native R ~ subunit 
are known to preferentially bind different adenine modified 
analogs of cAMP [5], a total of nine adenine-modified analogs 
with a broad range of site B to site A selectivities were studied 
(Table 2). The ability of these analogs to activate the wild-type 
and mutant holoenzyme is shown in Fig. 3a for 8-methylamino- 
cAMP (no. 1) and 6-benzoyl-cAMP (no. 9). 8-Methylamino- 
cAMP, which binds preferentially to site B, was nearly as effec- 
tive as cAMP in activating the wild-type holoenzyme and was 
even more effective compared to 6-Benzoyl-cAMP (no. 9) 
which preferentially binds to site A. However half-maximal 
activation of the mutant protein by the B-selective 8-Methylam- 
ino-cAMP shifted to higher concentrations as did activation by 
cAMP or A-selective analogs like 6-Benzoyl-cAME Fig. 3b 
shows the ability of these cAMP analogs to activate the mutant 
holoenzyme r lative to the wild type protein compared to their 
selectivity for site A/B. All analogs howed a shift to higher 
concentrations for their ability to activate the mutant enzyme 
(Table 2). In addition, analogs preferring site B were relatively 
weaker as activators of the mutant holoenzyme compared to 
A-selective analogs (Fig. 3b). 
4. Discuss ion 
cAMP-dependent protein kinase requires two functional 
cAMP binding sites for allosteric regulation. Kinetic evidence 
[22] as well as results from cAMP binding site mutants [10] and 
cAMP analogs [25,26] have indicated that kinase activation is
mediated via a sequential kinetic mechanism. First, cAMP 
Table 2 
Site selectivity (R ~) and apparent 
ified cAMP analogs 
activation constants of adenine-mod- 
No. cAMP analog Site selectivity Activation constants, 
Ka,ap (/.zM) 
R I ~B Wild-type Mutant 
1 8-Methylamino-cAMP 1/47 0.20 40 
2 8-Amino-cAMP 1/28 0.15 20 
3 2-Chloro-cAMP 1/13 0.28 25 
4 cAMP 1.0 0.17 5 
5 7-Deaza-cAMP 1.5 0.55 10 
6 8-p-Chlorophenylthio- 2.0 0.04 1.2 
cAMP 
7 N6-Benzyl-cAMP 3.9 0.31 9 
8 NI-Oxid-cAMP 4.0 0.50 17 
9 N6-Benzoyl-cAMP 19 0.50 10 
The cAMP analogs are listed according to their R l A/B selectivity [5]. 
Apparent activations constants  Ka.ap were determined asdescribed in
section 2.4. 
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binds at site B, which in turn mediates a conformational change 
which opens up site A. Only when both sites are occupied will 
the C subunit be released from the R t subunit dimer. The strong 
coupling between the two binding sites is reflected by a positive 
cooperativity (n = 1.5-1.6) [27,28]. In the Ala335Asp R I subunit 
we found that one high affinity cAMP binding site was appar- 
ently completely abolished, and we have shown that site B does 
not bind cAMP as a consequence of the mutation (Fig. 1, Table 
1). Furthermore, site B is uncoupled from site A which leads 
to a drastically reduced binding affinity for site A. Dissociation 
experiments showing a monophasic and rapid off-rate for site 
A lent further support o the conclusion that cAMP binding to 
site B was abolished (Fig. 1). 
Formation of mutant holoenzyme was extremely rapid (Fig. 
2), as has been observed for a number of other cAMP-binding 
site mutants with reduced or completely abolished cAMP bind- 
ing [10,11]. 
The combination of reduced affinity for site B and uncou- 
pling of the two cAMP binding sites results in a conformation 
which is favorable for association with the C subunit. Conse- 
quently, those mutants display a 'Ka, app-shift' which indicates 
that the mutant holoenzymes are more stable than wild-type 
enzyme. The activation and cAMP binding constants for the 
Ala335Asp mutant holoenzyme were similar (5 ¢tM and 2.8 ¢tM, 
respectively, Tables 1 and 2). The shift in the binding constants 
from 0.5pM to 2.8pM for site A in the R I subunit and holoen- 
zyme shows that (i) the catalytic subunit poses an additional 
barrier on cAMP binding to site A and (ii) binding of cAMP 
to site A is sufficient o activate the holoenzyme. Even in the 
holoenzyme complex the two sites are still uncoupled and site 
B does not impose a barrier on activation as is the case for 
wild-type holoenzyme. Activation studies with site selective 
cAMP analogs give further support to this hypothesis. The 
ability of site A selective analogs to preferentially activate mu- 
tant holoenzyme (Table 2, Fig. 3a,b) clearly indicates an activa- 
tion mechanism of holoenzyme primarily through this cAMP 
binding site. However, the nature of the uncoupling in molecu- 
lar terms is poorly understood. According to the CAP model 
[8] the side chain of Ala 335 lies in close proximity to the adenine 
moiety of cAMP. The environment of the adenine binding 
pocket is mostly hydrophobic as has been shown by cAMP- 
analog mapping [5,29] and molecular modeling studies [13,30]. 
Particularly the Ala/Asp substitution, which introduces a 
charge in the adenine binding site, disrupts high affinity cAMP 
binding. Consequently, the mutated site B can not contribute 
to the positive cooperativity for binding to site A, hence the KD 
measured for site A reflects the 'true' cAMP binding affinity 
in the R T subunit. In conclusion, Ala 335 in site B plays a major 
role in proper cAMP binding for the efficient and correct func- 
tioning of cAMP-dependent protein kinase. 
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